Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 605 results
Filters: Author is Ribaudo, Heather J  [Clear All Filters]
Found 605 results.

Adult

Paredes R, Lalama CM, Ribaudo HJ, et al. "Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure." J. Infect. Dis.. 2010;201(5):662-71.
Kelesidis T, Tran TTien T, Stein JH, et al. "Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s." Clin. Infect. Dis.. 2015;61(4):651-60.
Brown TT, Chen Y, Currier JS, et al. "Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals." J. Acquir. Immune Defic. Syndr.. 2013;63(3):323-30.
Lalama CM, Jennings C, Johnson VA, et al. "Comparison of Three Different FDA-Approved Plasma HIV-1 RNA Assay Platforms Confirms the Virologic Failure Endpoint of 200 Copies per Milliliter Despite Improved Assay Sensitivity." J. Clin. Microbiol.. 2015;53(8):2659-66.
Li JZ, Paredes R, Ribaudo HJ, et al. "Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure." AIDS. 2012;26(2):185-92.
Ofotokun I, Na LH, Landovitz RJ, et al. "Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257." Clin. Infect. Dis.. 2015;60(12):1842-51.
Stein JH, Brown TT, Ribaudo HJ, et al. "Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection." AIDS. 2013;27(6):929-37.
Ribaudo HJ, Benson CA, Zheng Y, et al. "No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT." Clin. Infect. Dis.. 2011;52(7):929-40.
Bartlett JA, Ribaudo HJ, Wallis CL, et al. "Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings." AIDS. 2012;26(11):1345-54.
Ribaudo HJ, Kuritzkes DR, Lalama CM, et al. "Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts." J. Infect. Dis.. 2008;197(7):1006-10.
Ribaudo HJ, Smith KY, Robbins GK, et al. "Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis." Clin. Infect. Dis.. 2013;57(11):1607-17.
Kumarasamy N, Aga E, Ribaudo HJ, et al. "Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230." Clin. Infect. Dis.. 2015;60(10):1552-8.
Stein JH, Ribaudo HJ, Hodis HN, et al. "A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness." AIDS. 2015;29(14):1775-83.
Overton ETurner, Chan ES, Brown TT, et al. "Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial." Ann. Intern. Med.. 2015;162(12):815-24.
Shikuma CM, Ribaudo HJ, Zheng Y, et al. "Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals." AIDS Res. Hum. Retroviruses. 2011;27(5):461-8.
Gulick RM, Ribaudo HJ, Shikuma CM, et al. "Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial." JAMA. 2006;296(7):769-81.
Gulick RM, Lalama CM, Ribaudo HJ, et al. "Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression." AIDS. 2007;21(7):813-23.
Vardhanabhuti S, Acosta EP, Ribaudo HJ, et al. "Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission." J. Infect. Dis.. 2013;208(4):662-71.

Pages